Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real‐world results from 18 378 patients in Egypt

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|47|3|421-431

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.47, Iss.3, 2018-02, pp. : 421-431

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C‐related cirrhosis, genotype 4

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 5, 2018-03 ,pp. : 674-679

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post‐transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study

By  

CLINICAL TRANSPLANTATION (ELECTRONIC), Vol. 32, Iss. 2, 2018-02 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real‐world experience

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 6, 2018-03 ,pp. : 838-844

John Wiley & Sons Inc

Access to resources Recommend Favorite

Real‐world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 33, Iss. 3, 2018-03 ,pp. : 710-717

John Wiley & Sons Inc

Access to resources Recommend Favorite

P152: Real‐world effectiveness of Ledipasvir/Sofosbuvir 8 weeks chronic hepatitis C treatment

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. S2, 2015-06 ,pp. : 95-96

John Wiley & Sons Inc

Access to resources Recommend Favorite